A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Condition:   Alopecia Areata Interventions:   Drug: CTP-543, 8 mg BID;   Drug: CTP-543, 12 mg BID;   Drug: Placebo, BID Sponsor:   Concert Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials